Literature DB >> 25733705

CCR 20th anniversary commentary: In the beginning, there was PS-341.

Beverly A Teicher1, Kenneth C Anderson2.   

Abstract

Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708). ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25733705      PMCID： PMC4349205          DOI： 10.1158/1078-0432.CCR-14-2549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Authors:  Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

2.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Authors:  J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Authors:  Dharminder Chauhan; Ze Tian; Bin Zhou; Deborah Kuhn; Robert Orlowski; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2011-06-30       Impact factor: 12.531

4.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

Authors:  V J Palombella; O J Rando; A L Goldberg; T Maniatis
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

5.  The proteasome inhibitor PS-341 in cancer therapy.

Authors:  B A Teicher; G Ara; R Herbst; V J Palombella; J Adams
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

6.  Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Dalia Quwaider; Miriam Canavese; Enrique M Ocio; Ze Tian; Juan F Blanco; Allison J Berger; Carlos Ortiz-de-Solorzano; Teresa Hernández-Iglesias; Anton C M Martens; Richard W J Groen; Joaquín Mateo-Urdiales; Susana Fraile; Miguel Galarraga; Dharminder Chauhan; Jesús F San Miguel; Noopur Raje; Mercedes Garayoa
Journal:  Clin Cancer Res       Date:  2014-01-31       Impact factor: 12.531

7.  A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Authors:  Owen A O'Connor; A Keith Stewart; Marcy Vallone; Christopher J Molineaux; Lori A Kunkel; John F Gerecitano; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

8.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

9.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Authors:  Mark H Ma; Hank H Yang; Kimberly Parker; Steven Manyak; Jeffrey M Friedman; Cibby Altamirano; Zhi-qun Wu; Mitesh J Borad; Malka Frantzen; Evanthia Roussos; Jason Neeser; Amy Mikail; Julian Adams; Nelida Sjak-Shie; Robert A Vescio; James R Berenson
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531
  9 in total
  6 in total

Review 1.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

2.  Valosin-containing protein (VCP)-Adaptor Interactions are Exceptionally Dynamic and Subject to Differential Modulation by a VCP Inhibitor.

Authors:  Liang Xue; Emily E Blythe; Elyse C Freiberger; Jennifer L Mamrosh; Alexander S Hebert; Justin M Reitsma; Sonja Hess; Joshua J Coon; Raymond J Deshaies
Journal:  Mol Cell Proteomics       Date:  2016-07-12       Impact factor: 5.911

Review 3.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

4.  Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

Authors:  Jonghoon Park; Eok Park; Cheol-Kyu Jung; Seung-Wan Kang; Byung Gyu Kim; Youngjoo Jung; Tae Hun Kim; Ji-Young Lim; Sung-Eun Lee; Chang-Ki Min; Kwang-Ai Won
Journal:  BMC Cancer       Date:  2016-03-24       Impact factor: 4.430

5.  2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.

Authors:  Yuan Qing Qu; Flora Gordillo-Martinez; Betty Yuen Kwan Law; Yu Han; Anguo Wu; Wu Zeng; Wai Kei Lam; Charles Ho; Simon Wing Fai Mok; Hu Qiang He; Vincent Kam Wai Wong; Renxiao Wang
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

Review 6.  Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.

Authors:  Rachel L Mynott; Craig T Wallington-Beddoe
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.